Timothy Hsu, MD
Timothy Hsu MD is former Sr VP and Chief Medical Officer at Neurovance and at Euthymics Bioscience, where he directed the development of novel triple reuptake inhibitors (TRI) for both ADHD and MDD. Prior to that Tim was head of clinical development for the Asia/Pacific region at Teva Branded Pharmaceuticals, head of psychiatry clinical development at Eisai Pharmaceuticals, and head of CNS clinical development at Somaxon Pharmaceuticals.
Earlier in his career Tim served in both clinical development and medical affairs roles at Pfizer Neuroscience, where he directed teams working on Geodon and Lyrica, as well as various early stage compounds for CNS. Prior to joining Pfizer, Tim was on the psychiatry faculty at the Univ. of Michigan medical school with a subspecialty in Sleep Medicine.
Tim completed residencies in both internal medicine and psychiatry at the Mayo Clinic, and clinical fellowships in sleep medicine as well as an NIMH-sponsored postdoctoral fellowship at the University of Michigan. Tim completed his MD degree at Michigan State University.
Chief Medical Officer